Business
Mesoblast reveals more COVID trials needed, shares tumble – Sydney Morning Herald
The Melbourne biotech has been advised by the US medicines regulator that it will need to run another trial of its COVID-19 treatment…
Stem cell treatments maker Mesoblast faces a new hurdle after the US medicines regulator told the company it would need to run another trial of its COVID-19 treatment before it could apply for emergency approvals.
Shares in the Melbourne biotech fell 15.9…
Continue Reading
-
Noosa News17 hours agoForum responds to urgent homelessness issues in Nambour
-
Noosa News16 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
General19 hours agoFirst home buyers score early access to deposit scheme
-
Business14 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick